BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 234 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $669,754 | +4.3% | 94,598 | +3.7% | 0.00% | 0.0% |
| Q2 2023 | $642,287 | -14.0% | 91,234 | +1.9% | 0.00% | -20.0% |
| Q1 2023 | $746,613 | -25.9% | 89,522 | +2.0% | 0.01% | -28.6% |
| Q4 2022 | $1,007,255 | -9.3% | 87,740 | -0.4% | 0.01% | -12.5% |
| Q3 2022 | $1,110,000 | +20.8% | 88,060 | +1.4% | 0.01% | +33.3% |
| Q2 2022 | $919,000 | -36.8% | 86,816 | -2.9% | 0.01% | -25.0% |
| Q1 2022 | $1,453,000 | +9.7% | 89,386 | -6.6% | 0.01% | +14.3% |
| Q4 2021 | $1,325,000 | -5.2% | 95,678 | -1.7% | 0.01% | 0.0% |
| Q3 2021 | $1,398,000 | -11.2% | 97,315 | -2.3% | 0.01% | +40.0% |
| Q2 2021 | $1,575,000 | +50.4% | 99,627 | -3.2% | 0.01% | +25.0% |
| Q1 2021 | $1,047,000 | +36.9% | 102,952 | +0.3% | 0.00% | +33.3% |
| Q4 2020 | $765,000 | +110.7% | 102,680 | -2.8% | 0.00% | +50.0% |
| Q3 2020 | $363,000 | -19.3% | 105,626 | +12.0% | 0.00% | 0.0% |
| Q2 2020 | $450,000 | +147.3% | 94,339 | +3.6% | 0.00% | +100.0% |
| Q1 2020 | $182,000 | -43.1% | 91,039 | -1.8% | 0.00% | 0.0% |
| Q4 2019 | $320,000 | +60.8% | 92,742 | +33.4% | 0.00% | 0.0% |
| Q3 2019 | $199,000 | -24.9% | 69,534 | -0.7% | 0.00% | 0.0% |
| Q2 2019 | $265,000 | -53.2% | 70,018 | +0.6% | 0.00% | -50.0% |
| Q1 2019 | $566,000 | -2.4% | 69,582 | -3.1% | 0.00% | 0.0% |
| Q4 2018 | $580,000 | +5.1% | 71,836 | -0.8% | 0.00% | 0.0% |
| Q3 2018 | $552,000 | +50.0% | 72,390 | +12.8% | 0.00% | +100.0% |
| Q2 2018 | $368,000 | +23.1% | 64,154 | +2.4% | 0.00% | 0.0% |
| Q1 2018 | $299,000 | -7.7% | 62,634 | -5.1% | 0.00% | 0.0% |
| Q4 2017 | $324,000 | +15.3% | 66,002 | +22.9% | 0.00% | 0.0% |
| Q3 2017 | $281,000 | +1.8% | 53,685 | +8.1% | 0.00% | 0.0% |
| Q2 2017 | $276,000 | -27.4% | 49,671 | +9.8% | 0.00% | 0.0% |
| Q1 2017 | $380,000 | +42.3% | 45,230 | +7.1% | 0.00% | 0.0% |
| Q4 2016 | $267,000 | -99.9% | 42,241 | -0.3% | 0.00% | 0.0% |
| Q3 2016 | $186,764,000 | +55.5% | 42,350 | +0.2% | 0.00% | 0.0% |
| Q2 2016 | $120,092,000 | -5.4% | 42,286 | -6.0% | 0.00% | – |
| Q1 2016 | $127,000,000 | -72.3% | 44,974 | +1.1% | 0.00% | -100.0% |
| Q4 2015 | $458,000,000 | +88832.0% | 44,474 | -1.5% | 0.00% | 0.0% |
| Q3 2015 | $515,000 | -99.9% | 45,148 | +0.7% | 0.00% | -33.3% |
| Q2 2015 | $669,581,000 | +59.8% | 44,848 | -3.4% | 0.00% | +50.0% |
| Q1 2015 | $419,101,000 | -27.6% | 46,412 | -2.5% | 0.00% | -33.3% |
| Q4 2014 | $578,962,000 | +22.9% | 47,612 | -1.1% | 0.00% | +50.0% |
| Q3 2014 | $470,956,000 | -21.1% | 48,155 | +2.8% | 0.00% | -33.3% |
| Q2 2014 | $597,210,000 | +5544.7% | 46,840 | +4584.0% | 0.00% | – |
| Q1 2014 | $10,580,000 | -60.2% | 1,000 | -71.4% | 0.00% | – |
| Q4 2013 | $26,600,000 | +4.4% | 3,500 | 0.0% | 0.00% | – |
| Q3 2013 | $25,480,000 | -56.0% | 3,500 | -90.6% | 0.00% | – |
| Q2 2013 | $57,917,000 | – | 37,366 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 864,916 | $13,674,000 | 13.71% |
| Sarissa Capital Management LP | 4,261,000 | $67,366,000 | 5.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $30,367,000 | 4.18% |
| HealthCor Management, L.P. | 3,248,100 | $51,352,000 | 2.05% |
| Parkman Healthcare Partners LLC | 351,961 | $5,565,000 | 1.22% |
| Bain Capital Public Equity Management II, LLC | 1,560,730 | $24,675,000 | 1.06% |
| Baker Brothers Advisors | 12,710,818 | $200,958,000 | 0.88% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,835,000 | $44,821,000 | 0.80% |
| Biondo Investment Advisors, LLC | 265,840 | $4,203,000 | 0.72% |
| EAM Global Investors LLC | 157,065 | $2,483,000 | 0.69% |